<DOC>
	<DOCNO>NCT02322671</DOCNO>
	<brief_summary>This study design estimate bioavailability montelukast 5 milligram ( mg ) montelukast sodium ( GW483100 ) test formulation relative 5 mg montelukast sodium reference chewable tablet ( innovator product ) . It open-label , randomize , single dose , three-way cross , six sequence study 18 healthy human subject . Each subject participate three treatment period . Subjects randomize one six sequence administer one three treatment A , B C treatment period , Treatment A 5mg chewable tablet reference 5 mg montelukast sodium reference chewable tablet ( innovator product ) , Treatment B test formulation 1 : 5mg montelukast sodium ( GW483100 ) chewable tablet Treatment C test formulation 2 : 5mg montelukast sodium ( GW483100 ) chewable tablet . The treatment period separate washout period 7 14 day . Total duration study subject approximately 8 week screen follow-up visit .</brief_summary>
	<brief_title>Relative Bioavailability Study Two Montelukast Sodium ( GW483100 ) 5 Milligrams ( mg ) Chewable Tablets One Reference Montelukast Sodium 5 mg Chewable Tablet Healthy Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Respiration Disorders</mesh_term>
	<mesh_term>Respiratory Tract Diseases</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Male female age 18 65 year age inclusive , time signing informed consent . Healthy determine investigator medically qualify designee base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include investigator consultation Medical Monitor require , agree document find unlikely introduce additional risk factor interfere study procedure . Body weight &gt; = 50 kilogram ( kg ) Body mass index ( BMI ) within range 19 24.9 kilogram per square meter ( kg/m^2 ) ( inclusive ) . Male subject Female subject : eligible participate pregnant ( confirm negative serum human chorionic gonadotrophin [ hCG ] test ) , lactate , least one follow condition applies : Nonreproductive potential define : Premenopausal females one following : Documented tubal ligation Documented hysteroscopic tubal occlusion procedure followup confirmation bilateral tubal occlusion Hysterectomy Documented Bilateral Oophorectomy Postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) estradiol level consistent menopause ( refer laboratory reference range confirmatory level ) ] . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one highly effective contraception method wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrolment . Reproductive potential agrees follow one option list GlaxoSmithKline ( GSK ) Modified List Highly Effective Methods Avoiding Pregnancy Females Reproductive Potential ( FRP ) requirement 30 day prior first dose study medication [ least five terminal halflives OR continue pharmacologic effect end , whichever long ] last dose study medication completion followup visit . GSK Modified List Highly Effective Methods Avoiding Pregnancy FRP This list apply FRP sex partner , prefer usual lifestyle subject continue abstinent penilevaginal intercourse long term persistent basis . Contraceptive subdermal implant meet standard operate procedure ( SOP ) effectiveness criterion include &lt; 1 % rate failure per year , state product label Intrauterine device intrauterine system meet SOP effectiveness criterion include &lt; 1 % rate failure per year , state product label Oral Contraceptive , either combined progestogen alone Injectable progestogen Contraceptive vaginal ring Percutaneous contraceptive patch Male partner sterilisation documentation azoospermia prior female subject 's entry study , male sole partner subject Male condom combine vaginal spermicide ( foam , gel , film , cream , suppository ) follow 3 situation low risk developmental toxicity : Vaccines ; Monoclonal antibody target biology concern ; Compounds complete reproductive toxicology package show signal developmental toxicity . These allow method contraception effective use consistently , correctly accordance product label . The investigator responsible ensure subject understand properly use method contraception . Male subject female partner child bear potential must comply follow contraception requirement time first dose study medication [ least five halflives study medication cycle spermatogenesis follow five terminal halflives ] last dose study medication . Vasectomy documentation azoospermia . Male condom plus partner use one contraceptive option : Contraceptive subdermal implant meet SOP effectiveness criterion include &lt; 1 % rate failure per year , state product label Intrauterine device intrauterine system meet SOP effectiveness criterion include &lt; 1 % rate failure per year , state product label Oral Contraceptive , either combined progestogen alone . Injectable progestogen Contraceptive vaginal ring Percutaneous contraceptive patch These allow method contraception effective use consistently , correctly accordance product label . The investigator responsible ensure subject understand properly use method contraception . Capable give write informed consent , include compliance requirement restriction list consent form . Alanine aminotransferase ( ALT ) bilirubin &gt; 1.5 x upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) Corrected QT ( QTC ) &gt; 450 millisecond ( msec ) NOTES : The QTc QT interval correct heart rate accord Bazett 's formula ( QTcB ) , Fridericia 's formula ( QTcF ) , and/or another method , machineread manually overread . The specific formula use determine eligibility discontinuation individual subject determine prior initiation study . In word , several different formula use calculate QTc individual subject low QTc value use include discontinue subject trial . For purpose data analysis , QTcB , QTcF , another QT correction formula , composite available value QTc use specify Reporting Analysis Plan ( RAP ) . No concomitant medication take subject participate study . Refer Study Protocol detail . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 gram alcohol : halfpint ( ~240 milliliter [ mL ] ) beer , 1 glass ( 125 mL ) wine 1 ( 25 mL ) measure spirit . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . History sensitivity heparin heparininduced thrombocytopenia . History sensitivity study medication , component thereof history drug allergy , opinion investigator Medical Monitor , contraindicate participation . Subjects phenylketonuria Presence hepatitis B surface antigen ( HBsAg ) , positive hepatitis C antibody test result screen within 3 month prior first dose study treatment . For potent immunosuppressive agent , subject presence hepatitis B core A positive prestudy drug/alcohol screen . A positive test Human Immunodeficiency Virus ( HIV ) antibody . Where participation study would result donation blood blood product excess 500 mL within 90 day period . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 90 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Gastrointestinal disease gastrointestinal surgical history affect absorption investigational drug . Any symptom systolic Blood pressure ( BP ) &lt; 95 millimeter mercury ( mmHg ) Pregnant female determine positive serum hCG test screen prior dose Lactating female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>chewable tablet</keyword>
	<keyword>montelukast sodium</keyword>
	<keyword>healthy adult subject</keyword>
	<keyword>relative bioavailability</keyword>
	<keyword>GW483100</keyword>
</DOC>